MUC4 mucin is a high molecular weight transmembrane glycoprotein that plays important roles in tumour biology. It is aberrantly expressed in pancreatic adenocarcinoma, while not being detectable in the normal pancreas. Previous studies have demonstrated that the cystic fibrosis transmembrane conductance regulator (CFTR), a chloride channel that is defective in CF, is implicated in multiple cellular functions, including gene regulation. In the present study, using a CFTR-defective pancreatic cancer cell line and its derived subline expressing functional CFTR, we report that MUC4 expression is negatively regulated by CFTR. Short-interfering RNA (siRNA)-mediated silencing of CFTR also leads to an increased expression of MUC4. Additionally, our results suggest that CFTR-mediated regulation of MUC4 is cell densitydependent and is achieved by transcriptional and posttranslational mechanisms. Moreover, in a panel of pancreatic cancer cell lines and normal pancreas, we observed that CFTR was downregulated in pancreatic cancer cells and negatively correlated with MUC4 in most cases. An aberrant expression of MUC4 was also detected in the CF pancreas. Downregulation of CFTR in pancreatic adenocarcinoma and its inverse association with the tumour-linked mucin, MUC4, indicate novel function(s) of CFTR in pancreatic tumour biology and suggest the implication of new signalling pathway(s) in MUC4 regulation.
MUC4 mucin is a high molecular weight transmembrane glycoprotein that plays important roles in tumour biology. It is aberrantly expressed in pancreatic adenocarcinoma, while not being detectable in the normal pancreas. Previous studies have demonstrated that the cystic fibrosis transmembrane conductance regulator (CFTR), a chloride channel that is defective in CF, is implicated in multiple cellular functions, including gene regulation. In the present study, using a CFTR-defective pancreatic cancer cell line and its derived subline expressing functional CFTR, we report that MUC4 expression is negatively regulated by CFTR. Short-interfering RNA (siRNA)-mediated silencing of CFTR also leads to an increased expression of MUC4. Additionally, our results suggest that CFTR-mediated regulation of MUC4 is cell densitydependent and is achieved by transcriptional and posttranslational mechanisms. Moreover, in a panel of pancreatic cancer cell lines and normal pancreas, we observed that CFTR was downregulated in pancreatic cancer cells and negatively correlated with MUC4 in most cases. An aberrant expression of MUC4 was also detected in the CF pancreas. Downregulation of CFTR in pancreatic adenocarcinoma and its inverse association with the tumour-linked mucin, MUC4, indicate novel function(s) of CFTR in pancreatic tumour biology andIntroduction MUC4, a member of the membrane-bound mucin gene family, was identified among the most differentially expressed genes in pancreatic adenocarcinoma with an undetectable expression in the normal pancreas (Andrianifahanana et al., 2001; Iacobuzio-Donahue et al., 2003) . Recent studies have provided compelling evidence implicating the MUC4 mucin in the pathogenesis of pancreatic cancer (Komatsu et al., 2000; Swartz et al., 2002; Singh et al., 2004) . Expression analysis of MUC4 in increasing grade pancreatic intraepithelial neoplastic lesions (PanINs) and pancreatic adenocarcinoma demonstrated a positive correlation of MUC4 with the disease progression (Swartz et al., 2002) . Moreover, silencing of MUC4 expression in pancreatic cancer cells led to reduced tumor growth and metastasis, suggesting an important role of MUC4 in pancreatic tumour development (Singh et al., 2004) . MUC4 was shown to potentiate its tumour promoter function by altering the growth and behavioural properties of the tumour cell, and/or in part, by modulating the expression of receptor tyrosine kinase ErbB2/HER2/neu (Singh et al., 2004) . In other studies, sialo-mucin complex (SMC), a rat homologue of MUC4 has also been shown to play multiple roles in tumour cell biology. SMC/Muc4 acts as a ligand for ErbB2/HER2 inducing its limited phosphorylation (Jepson et al., 2002) . The overexpression of SMC results in the suppression of both cell adhesion and immune killing of tumour cells, enhanced tumour growth and potentiation of metastasis (Komatsu et al., 1999 (Komatsu et al., , 2000 (Komatsu et al., , 2001 . However, despite all these pathobiological implications of MUC4 in tumour biology, suggesting its importance as a potential therapeutic target, the molecular mechanisms implicated in its regulation have remained ill-defined.
Cystic fibrosis transmembrane conductance regulator (CFTR), a transmembrane glycoprotein, is mainly recognized for its function as a cyclic AMP-mediated chloride channel (Riordan et al., 1989; Welsh and Smith 1993) . It is expressed in a wide variety of epithelial cells including pancreatic ductal cells (Namkung et al., 2003) .
Mutations in the CFTR gene result in the production of a non-or partially-functional CFTR protein, leading to the development of cystic fibrosis (CF), the most common lethal hereditary disorder in the Caucasian population (Zielenski and Tsui, 1995) . CFTR dysfunction results in the protein secretion and ion transport defect, giving rise to multiple pathophenotypes. The hallmark of CF is the accumulation of abnormally thick mucus, leading to the obstruction of intestine, lungs and pancreatic and bile ducts. It is also suspected that the lack of CFTR function, in association with environmental factors, may be associated with the major type of chronic pancreatic pathology, that is, pancreatitis and pancreatic cancer (Malats et al., 2001) . In fact, a recent study has clearly indicated a link between the CFTR mutation carrier status and early-onset of pancreatic adenocarcinoma (McWilliams et al., 2005) .
Our interest in investigating the association between CFTR and MUC4 mucin expression was incited from the recent reports indicating the involvement of the CFTR dysfunction in the aberrant expression and biochemical properties of mucins (Gonzalez-Guerrico et al., 2002; Thomsson et al., 2002; Malmberg et al., 2006) . In an effort to elucidate the association between CFTR and MUC4, we examined the expression of CFTR and the MUC4 mucin in normal pancreas and pancreatic adenocarcinoma cells. CFTR expression was not detected in most tumour cell lines, while it was expressed in normal pancreas and cultured ductal cells showing an inverse pattern of expression with that of MUC4. To test this inverse association between CFTR and MUC4 expression, we extended our study in a pancreatic tumour cell line derived from a CF patient (CFPAC1) and its CFTR corrected subline, CFPAC-PLJ-CFTR. Our studies clearly demonstrate that MUC4 expression is negatively modulated by CFTR and that transcriptional and post-translational mechanisms are implicated in its regulation.
Results

CFTR expression is inversely associated with MUC4 expression
We have previously shown that MUC4 is aberrantly expressed in pancreatic tumour tissue and cell lines, while it remains undetectable in the normal pancreas (Andrianifahanana et al., 2001) . To examine the correlation between CFTR and MUC4 expression, we performed reverse transcriptase-polymerase chain reaction (RT-PCR) analysis on 16 pancreatic cancer cell lines along with the cultured normal ductal cells and normal pancreas. Consistent with previous report, an aberrant expression of MUC4 was observed in 13 out of 16 (81%) pancreatic cancer cell lines, whereas it was not detectable in normal ductal cells and pancreas. In contrast, while CFTR expression was observed in ductal cells and normal pancreas, only three out of 16 (19%) pancreatic cancer lines expressed detectable levels of CFTR transcript, exhibiting an inverse correlation between CFTR and MUC4 expression in most cases (Figure 1a ).
To further examine if MUC4 expression is influenced by the presence of CFTR or vice versa, we studied the expression of MUC4 in CFTR-expressing (CFPAC-PLJ-CFTR) and nonexpressing (CFPAC1 and CFPAC-PLJ) cell lines of the same genotypic lineage. The parental CFPAC1 cell line has been derived from a CF patient carrying a DF508 mutation in the CFTR (Schoumacher et al., 1990) . The CFPAC1 cells were transduced with a retroviral vector (PLJ) and the CFTR-expressing viral construct (PLJ-CFTR). CFPAC-PLJ subline represents a mock-transfected clone, and the CFPAC-PLJ-CFTR subline has been derived from a CFTR-expressing clone. The functionality of the CFTR protein has been demonstrated (Drumm et al., 1990) . Our results show that cells expressing functional CFTR (CFPAC-PLJ-CFTR) have a decreased level (B50%) of MUC4 transcripts (Figure 1b ) compared to the cells lacking CFTR function (CFPAC1 and CFPAC-PLJ). Moreover, as determined by immunoblot analysis, MUC4 protein levels exhibit on an average B70% (range 50-90%) decreased signal in cells expressing a functional CFTR (Figure 1c ). By immunoblotting, two bands were detected in correspondence to the two MUC4 transcripts observed by Northern blot analysis (Figure 1b) . Therefore, these findings suggest that MUC4 is differentially expressed at both mRNA and protein levels in CFTR-expressing versus nonexpressing cells.
Short-interfering RNA (siRNA)-mediated silencing of CFTR upregulates MUC4 expression CFPAC1 and derived sublines were generated more than a decade ago (Drumm et al., 1990) and have undergone numerous passages. Therefore, in order to ascertain that the differential MUC4 expression in CFPAC1 cells is indeed associated with CFTR, we employed an siRNA-mediated gene-silencing approach to validate the role of CFTR in MUC4 regulation. The siRNA oligonucleotide located 77 base pair downstream of ATG was designed to target the human CFTR coding sequence. CFPAC-PLJ-CFTR cells were transfected with siRNAs for different time periods and MUC4 RNA and protein levels were assessed by RT-PCR and immunofluorescence analyses, respectively. An inhibition of CFTR expression was observed at 48 and 72 h with a concomitant increase in the expression of MUC4 at both mRNA and protein levels (Figure 2a and b) . These results clearly demonstrate that CFTR is implicated in MUC4 regulation.
MUC4 expression is differentially regulated by CFTR in a cell density-dependent manner CFPAC-PLJ-CFTR cells showed a relatively variable expression pattern of MUC4 at the protein level compared to a consistent downregulation at the mRNA level (see Figure 1b and c). In consideration of these findings, we sought to investigate whether MUC4 expression is differentially regulated at mRNA and protein levels depending on the cell density in CFTRexpressing versus -nonexpressing cells. Cells were seeded at low density and total RNA and protein were extracted at three time intervals; 48 h (B30% confluence), 96 h (B70% confluence) and 144 h (near confluence). MUC4 expression was determined by Northern and immunoblot analyses (Figure 3a and b). Our data show that relative MUC4 expression in CFTR-expressing versus -nonexpressing cells remains consistent at the mRNA level, but it is differentially regulated at the protein level depending on the cell density (Figure 3a and b) .
Stability of MUC4 transcript and protein
Our previous data indicated that MUC4 expression is regulated by CFTR in pancreatic cancer cells ( Figure  1b, c and 2) . Moreover, the cell density-dependent differential pattern of expression at the mRNA and protein levels (Figure 3a and b) pointed out that multiple mechanisms might be involved in the regulation of MUC4 expression. In order to determine whether changes in mRNA and protein stability could contribute to the downregulation of MUC4 in CFTR expressing cells, the turnover of MUC4 mRNA and protein was determined. MUC4 transcription and translation was inhibited in near confluent cells using actinomycin D (a transcription inhibitor) and cycloheximide (a translation inhibitor), respectively. Cell viability in the presence of actinomycin D and cycloheximide was >90% in both CFTR expressing and nonexpressing cell lines (at 12 h), as measured by trypan blue exclusion. After addition of GAPDH was used as an internal control. (b) Northern blot analysis of MUC4 expression in CFPAC1 (pancreatic tumour cell line derived from CF patient carrying DF508-CFTR mutation), CFPAC-PLJ (retroviral vector transfected) and CFPAC-PLJ-CFTR (functional CFTR expressing) cell lines. Bars represent the fold difference in MUC4 expression normalized to GAPDH (mean7s.e., n ¼ 3; *Po0.05). (c) comparisons of MUC4 protein levels in CFPAC and transfected cell lines. Immunoblot analysis was performed on cellular lysates using either a MUC4-specific antibody or anti-PGK antibody to control for protein loading. Data presented are a representative of six different experiments. Bars represent the fold difference in MUC4 expression normalized to PGK to control for loading variation (mean7s.e., n ¼ 6; *P o 0.05).
actinomycin D and cycloheximide, a gradual decline was observed in MUC4 mRNA and protein levels, respectively. No significant difference, however, was detected in CFTR expressing versus nonexpressing pancreatic cancer cells with respect to MUC4 mRNA half-life (B12 h). However, the half-life of MUC4 protein was B12.3 h in CFTR nonexpressing cells (CFPAC1), compared with a shorter half-life (B6.7 h) in the CFTR expressing cells (Figure 4) . Thus, these results show that post-translational processes at the level of protein degradation/stabilization are involved in the CFTRdependent regulation of MUC4.
MUC4 promoter activity in CFTR-expressing versus -nonexpressing pancreatic cancer cells Having determined that MUC4 mRNA stability is not influenced by CFTR expression, we sought to investigate whether decreased transcriptional activity of MUC4 promoter could account for the reduced mRNA levels in CFTR expressing pancreatic cancer cells. Five differentially active promoter deletion mutants from both proximal (TATA-less) and distal (TATA-box containing) regions were utilized (Perrais et al., 2001) . Cells were co-transfected with pSV-bGal vector in order to normalize the transfection efficiency. Transcriptional activity of MUC4 promoter was detected in both the proximal and distal regions ( Figure 5 ). As shown in figure, fragments (1809, 1555) covering the region (À219/À1, À487/À1) have nearly the same activity; however, the fragment (2150) covering the region (-1187/À1) shows a considerable decrease in activity in CFPAC-PLJ-CFTR cells. Interestingly, the fragment (1641) covering the region (À3135/À2572) and containing the TATA-box was also less active in CFTR expressing cells. Nevertheless, another fragment (1959) containing the TATA-box, but lacking the sequence MUC4 expression is regulated by CFTR AP Singh et al from À3135 to À2782 (covering the region À2781/ À2572), showed similar activity in both CFTR expressing and nonexpressing cells. Table 1 shows a list of the transcription factor binding sites in various regions of the MUC4 promoter that we studied. Unique binding sites in both the TATA-less and TATA-box containing, differentially active promoter fragments are marked in bold and the binding sites that are uniquely common between both the fragments are underlined. Altogether, these observations indicate that the MUC4 expression at the mRNA level is transcriptionally regulated contingent on the presence/absence of a functional CFTR, and the regulatory elements are present in the À1187/À488 and À3135/À2782 regions of the promoter. Figure 3 Density dependent MUC4 expression is differentially regulated at mRNA and protein levels in CFTR-defective (CFPAC1 and CFPAC-PLJ) and CFTR corrected (CFPAC-PLJ-CFTR) cells. Total RNA and cellular lysates were prepared from the cell lines at three different cell densities (30%, 70% and near confluence). (a) Northern blot analyses show that differential MUC4 expression at transcript levels in CFTR-expressing and nonexpressing cells follows the similar pattern at varying cell densities. (b) Western blot analyses demonstrate that MUC4 protein levels are differentially regulated in CFTR-defective and CFTR-corrected cell lines with approximately 2.0-, 4.0-and 9.0-fold difference in MUC4 expression at 30%, 70% and near confluent cells. Bars represent the fold difference in MUC4 expression normalized to GAPDH or PGK (mean7s.e., n ¼ 3; *P o0.05).
Expression of MUC4 in noncancerous CF-pancreatic cells
To determine whether CFTR dysfunction/downregulation is directly associated with the aberrant expression of MUC4 in pancreas or whether it requires other signalling pathways altered in cancer cells, we studied the expression of MUC4 in normal and CF pancreas by Protein translation was inhibited in near confluent cells using cycloheximide treatment. Cellular lysates were prepared at different time points (0-24 hrs). Ten and 50 mg of total protein from cell lysates prepared from CFPAC1 and CFPAC-PLJ-CFTR, respectively, were resolved on SDS-agarose gels and analysed by immunoblotting. Densitometric analysis of MUC4 (both bands) were performed and the rate of protein degradation was determined. TCF-1, GATA-1, HOXA5, Sp1, Ets-2, RAR-a, RAR-b, LBP-1, IL6 RE-BP, Elk-1 À1187/À487
TCF-1, GATA-1, GATA-2, GATA-3, GATA-4, GATA-5a, GATA-6a, GATA-6b, Sp1, AP-1, Ets-1, Ets-2, E2F1, Elk-1, Cdx-1, hINF-a, HOXA5, IL6 RE-BP, RXR-a, LBP-1, Lyf-1, MAF, PEA3, c-myb À2781/À2572
LBP-1, Sp1, Elk-1, Ets-1, Ets-2, NF-kB, IL6 RE-BP, PEA3, Elf-1, TCF-1, GATA-1, c-myb, RAR-g À2781/À3135
IL6 RE-BP, LBP-1, GATA-1, GATA-2, GATA-3, GATA-4, Cdx-1, TCF-1, RAR-a, RAR-b, RAR-g, AP-1, Sp1, PEA3, Ets-2, Elf-1, Elk-1, MAF immunohistochemistry. As shown in Figure 6 , an aberrant expression of MUC4 was detected in human pancreatic tissue of CF patients, while it was not detectable in normal pancreas. A similar pattern of MUC4 expression was observed in all the available (CF pancreas, n ¼ 3 and normal pancreas, n ¼ 5) tissues, suggesting that MUC4 expression may be consequent to CFTR dysfunction.
Discussion
Despite the emerging importance of the MUC4 mucin in tumour biology (Komatsu et al., 1999 (Komatsu et al., , 2001 Singh et al., 2004) , the molecular mechanism(s) that lead to its deregulated expression in tumour cells is largely unknown. The expression of MUC4 is developmentally regulated and varies with the degree of tissue differentiation (Buisine et al., 1998 (Buisine et al., , 2000 . It is not expressed in the normal adult pancreas (Buisine et al., 2000; Andrianifahanana et al., 2001) . In pancreatic cancer and PanIN leisons, an aberrant expression of MUC4 has been observed (Swartz et al., 2002; Park et al., 2003) , suggesting that molecular changes (genetic or epigenetic) implicated in the tumour progression may be linked to the MUC4 dysregulation. In the present study, we investigated the role of the CFTR in MUC4 regulation. We demonstrate that CFTR expression is downregulated in pancreatic cancer cells (Figure 1a ) and is inversely associated with MUC4 expression ( Figures  1b, c and 2 ). MUC4 expression is variably regulated at mRNA and protein levels and is cell density-dependent (Figure 3a and b) . Furthermore, we show that CFTRmediated MUC4 regulation is achieved by distinct transcriptional and post-translational mechanisms (Figures 4 and 5) . It is also shown that CFTR dysfunction in CF pancreas leads to an upregulation of MUC4 ( Figure 6 ). CFTR has become a protein of interest for the past one and half decades, after the mutation in its gene was associated to one of the most lethal hereditary disorders, CF (Riordan et al., 1989; Welsh and Smith 1993) . Also, there has been a concern about the risk of various cancers in CF patients and carriers of CFTR mutations (Malats et al., 2001) . While a protective role of CFTR has been predicted for breast cancer and melanoma (Warren et al., 1991; Abraham et al., 1996) , a significant excess of digestive tract cancer in CF patients has also been reported (Sheldon et al., 1993; Neglia et al., 1995) . In the present study, we observed a reduced/negligible expression of CFTR in most (81%) pancreatic cancer cell lines, while it was expressed in cultured pancreatic ductal cells and normal pancreas ( Figure 1a) . As yet, the mutational status of CFTR in tested cell lines is not defined. Nonetheless, the downregulation of CFTR may also be a consequence of epigenetic changes subsequent to tumour-initiating mutations and/or altered cell signalling. The well-established molecular events that have been correlated with the pathogenesis of pancreatic ductal neoplasm include activation of the K-ras oncogene and inactivation of the tumour suppressor genes p16
INK4a in virtually all cases. Also, p53 and DPC4 mutations in about 60 and 50% of primary cancers, respectively, have been reported (Davenport et al., 1996 
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Activation of Ras or Src/PyMT pathways in colonic Caco-2 cells has been shown to downregulate CFTR expression via PKC-mediated signalling mechanism (Davenport et al., 1996) . Increased PKC activity, subsequent to prolonged phorbol esters, has also been shown to cause the degradation of CFTR in colonic and pancreatic ductal cells (Breuer et al., 1993; Winpenny et al., 1995) . In another report, interferon-gamma, a pro-inflammatory cytokine was shown to downregulate CFTR expression in colonic T84 cells, while activating EGFR in a Src kinase dependent manner (Uribe et al., 2002) . Studies have also suggested the role of interleukin-1 beta (IL1-b) in regulating the expression of CFTR via a mechanism that involves NF-kB activation (Cafferata et al., 2000 (Cafferata et al., , 2001 . Altogether, these studies suggest that altered cell signalling and microenvironment changes in cancer condition may be implicated in the downregulation of CFTR expression in pancreatic cancer. Aberrant expression of MUC4 in pancreatic adenocarcinoma has been reported previously by our laboratory and others (Andrianifahanana et al., 2001; Iacobuzio-Donahue et al., 2003) . MUC4 is not detectable in the normal pancreas (Buisine et al., 2000; Andrianifahanana et al., 2001) , and its de novo expression occurs in PanINs, which are recognized as preneoplastic lesions (Swartz et al., 2002; Park et al., 2003) . Studies on MUC4 expression and gene regulation have suggested a complex interplay of signalling pathways (Perrais et al., 2001; Soto et al., 2003; Mariette et al., 2004) . In the present report, CFTR expression displayed a negative association with MUC4 expression (Figure 1b and c) that was further confirmed by CFTR gene silencing using siRNA (Figure 2a and b) . Moreover, MUC4 expression seemed to be differentially regulated at mRNA and protein levels (Figure 3) . Altogether, these observations indicate that CFTR regulates MUC4 expression and multiple molecular mechanisms may be implicated in the regulatory network. Having said this, the question arises -how might CFTR regulate MUC4 expression? Recent findings have clearly indicated that CFTR regulates the expression of several genes, including mucins (Tabary et al., 1999; Steagall et al., 2000; Gonzalez-Guerrico et al., 2002; Estell et al., 2003) . CFTR regulates the MUC1 expression in CF-tracheobronchial epithelial cells via a mechanism that is mediated by c-src activation (Gonzalez-Guerrico et al., 2002) . Moreover, studies conducted in CFTR-knockout mice have demonstrated the aberrant mucus accumulation in the intestine (Thomsson et al., 2002) , and MUC1 has been reported to be an important contributor to the CF intestinal phenotype (Hinojosa-Kurtzberg et al., 2003) . Of interest, mucins from the intestine of CF mice showed increased fucosylation due to overexpression of Fucalpha 1-2 glycosyltransferase (Thomsson et al., 2002) . Furthermore, in a recent study, it has been indicated that increased MUC1 expression in CF-mouse intestine indirectly contribute to mucus overaccumulation via modulating the expression of other mucins by yet unknown mechanism(s) (Malmberg et al., 2006) . Altogether, it can be proposed that CFTR may regulate the gene expression by either direct or indirect mechanisms. Two alternate mechanisms have been suggested for CFTR-mediated gene regulation (Estell et al., 2003) : (1) CFTR chloride channel activity affects the cell membrane potential sufficiency triggering signal transduction; and (2) CFTR interacts with signalling adapter molecules and thereby modulates gene expression. Future investigations are needed to understand the nature of CFTR-dependent MUC4 regulation. Nonetheless, the current findings are of paramount importance in consideration of the previous observations that (1) MUC4 is implicated in pancreatic cancer development (Singh et al., 2004) and (2) CFTR mutation carrier status is linked to the early-onset of pancreatic adenocarcinoma (McWilliams et al., 2005) .
In a biological system, the precise control of gene expression can be achieved by multiple mechanisms and can occur at several regulatory steps starting from the transcription of the gene to the protein decay. We have identified at least two checkpoints that lead to the differential regulation of MUC4 in CFTR expressing versus nonexpressing pancreatic cancer cells: 1) transient transfection of MUC4 promoter-reporter constructs and assay of reporter activity ( Figure 5 ) suggested that the expression of MUC4 was transcriptionally regulated; 2) analysis of MUC4 protein stability indicated the increased turn-over of MUC4 in CFTR expressing (CFPAC-PLJ-CFTR) cells (Figure 4 ) that also seemed to be cell density dependent (Figure 3b ). The 5 0 untranslated region (UTR) of MUC4 possesses numerous putative binding sites for transcription factors (Perrais et al., 2001) , suggesting the involvement of multiple signalling pathways in the regulation of transcriptional activity of the MUC4 promoter. Our results demonstrate that cis-elements present in both the TATA box-containing and TATA-less regions of the MUC4 promoter regulate the transcriptional activity in a cell-specific (CFTR-dependent) manner. Analysis of the various promoter fragments studied showed the presence of multiple binding sites for transcription factors (Table 1 ). GATA2/3/4, Cdx-1, AP-1 and MAF seem to be of particular importance as their binding sites are uniquely present in both the differentially active promoter fragments (Table 1) . Involvement of these transcription factors in mediating cancer cell signaling and/or mucin gene expression has been demonstrated in previous studies (Dhakshinamoorthy and Jaiswal, 2002; Chen et al., 2004; Guo et al., 2004; Hokari et al., 2005) and should further be explored for the regulation of MUC4 expression. Stability of the protein is determined by certain inherent (structural) and external factors. The changes in the cellular environment (external factors) that occur under pathological conditions may lead to enhanced proteasomal and/or lysosomal degradation of the protein. The exact molecular mechanisms for the transcriptional and post-translational regulation of MUC4 are yet to be determined, albeit it is clear from the present study that CFTR, either directly or indirectly, modulates MUC4 gene expression. An aberrant expression of MUC4 was also observed in human pancreatic tissue of CF patients (Figure 6 ), suggesting a direct association of MUC4 expression with CFTR dysfunction. This, however, does not exclude the implication of other CFTR-independent signalling pathway(s) that are altered in cancer in MUC4 regulation. Moreover, in cancer cells, both CFTRdependent and -independent regulatory mechanisms may synergistically upregulate MUC4 expression. Based on the observations made in the present study and previously published reports; we have drawn a hypothetical model for MUC4 regulation by signalling pathways implicated in pancreatic cancer and CF (Figure 7) . We propose that loss of function of CFTR either due to gene mutation (as is the case in CF) (Welsh and Smith, 1993) or by downregulation of its expression (in pancreatic cancer) (present study) regulates the MUC4 expression both at transcriptional (regulation of promoter activity) and post-translational (by stabilizing MUC4 protein) levels.
In summary, we have shown that CFTR expression is downregulated in pancreatic cancer cells and is inversely associated with the expression of the tumour-linked mucin, MUC4. CFTR mediated regulation of MUC4 occurs by transcriptional and post-translational mechanisms and is cell density-dependent. Further elucidation of the signalling pathways implicated will help us understand the dysregulation of MUC4 in pancreatic adenocarcinoma and propose novel functions of CFTR in pancreatic cancer development by altering gene expression.
Materials and methods
Reagents
All reagents were purchased from Sigma (St Louis, MO, USA) except for the following: Dulbecco's phosphate-buffered saline, fetal bovine serum, trypsin-ethylenediaminetetraacetic acid (EDTA) solution and penicillin/streptomycin solution, all cell culture media (Life Technologies Inc., Gaithersburg, MD, USA); first strand cDNA synthesis kit, Genescreen nylon membranes (Perkin-Elmer Life Sciences Inc., Boston, MA, USA); restriction enzyme, luciferase and b-galactosidase assay kits (Promega, Madison, WI, USA); all PCR reagents (Fermentas, Hanover, MD, USA); Fugene s transfection reagent, protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany); HRP-labelled secondary antibodies, ECL kit; random primer labelling kit (Amersham Pharmacia Biotech, UK); PVDF membrane (Millipore, Bradford, MA, USA); ABC Elite kit (Vector Laboratories, Burlingame, CA, USA). Proposed model for CFTR-mediated MUC4 regulation in pancreatic cancer and CF. This model has been generated based on the current observations and previous studies. Mutation in the k-ras gene leading to its activation are observed in virtually all the cases of pancreatic cancer (Hruban et al., 2000) . Activation of ras may downregulate the expression of CFTR via a regulatory mechanism mediated by PKC (Davenport et al., 1996) . Loss of function/expression of CFTR protein leads to an upregulation of MUC4 via transcriptional (promoter-dependent) and post-translational (protein stability) mechanisms.
Cell-lines and tissue specimens
CaPan1, CaPan2, HPAF, HPAC, HS766T, T3M4 and CFPAC1) and immortalized normal pancreatic ductal cells were examined for the CFTR expression. Three frozen normal pancreatic tissue samples obtained from healthy organ donors were also used in this study. Association between CFTR and MUC4 expressions was studied in CFPAC1 cells transduced with a retroviral vector (CFPAC-PLJ) or with the retroviral construct expressing functional CFTR (CFPAC-PLJ-CFTR). All cells were cultured in ATCC specified cell culture media, supplemented with 10% fetal bovine serum, penicillin (100 mg/ml) and streptomycin (100 mg/ml). Additionally, seven formalin-fixed pancreatic tissue samples from normal autopsy specimen (n ¼ 4) and from patients with CF (n ¼ 3) were also procured from Unite INSERM, Lille, France.
RNA isolation
Tissue samples were manually ground to a fine powder in liquid nitrogen with mortar and pestle and resuspended in modified guanidinium isothiocyanate (GITC) buffer (Debailleul et al., 1998) . Cultured adenocarcinoma cells at subconfluence were rinsed twice in ice-cold phosphate-buffered saline and solubilized in GITC buffer. Total RNA was extracted from pancreatic tumour cell lines, immortalized normal pancreatic ductal cells and normal pancreatic tissue samples by using guanidine isothiocyanate-cesium chloride ultracentrifugation method, as described previously (Debailleul et al., 1998) . RNA concentration was measured spectrophotometrically and its integrity was analysed by electrophoresis on a formaldehyde agarose gel.
Reverse transcription-polymerase chain reaction Two micrograms of RNA were reverse transcribed using the first-strand cDNA synthesis kit and oligo(dT) primers, according to the manufacturer's instructions. PCR amplifications were carried out with 100 ng of first-strand pancreatic cell line cDNA in 50-ml reaction volumes. The reaction mixture was subjected to an initial denaturation at 941C for 4 min, followed by 25-30 cycles at 941C for 45 s (denaturation), 551C for 45 s (annealing), and 721C for 1 min (elongation) with a final extension step for an additional 15 min at 721C. Oligonucleotide primer pairs for CFTR, MUC4 and glyceraldehyde phosphate dehydrogenase (GAPDH) were synthesized at molecular biology core facility (sense CFTR, 5 0 -CAC CATCTCATTCTGCATTGTT-3 0 ; antisense CFTR, 5 0 -TCCA GGAGACAGGAGCATCTCCTTCTAATG-3 0 : sense MUC4, CGCGGTGGTGGAGGCGTTCTT; antisense MUC4, GAA GAATCCTGACAGCCTTCA: sense GAPDH, TGAAGGTC GGAGTCAACGGATTTGGT; antisense GAPDH, CATGT GGGCCATGAGGTCCACCAC).
Northern blotting
Total RNA (20-40 mg) from each sample were electrophoresed on 1.0% agarose gel containing 0.66 M formaldehyde and transferred onto nitrocellulose via capillary blotting. After ultraviolet crosslinking, membranes were prehybridized in a buffer containing of 5 Â SSC, 50% formamide, 10 Â Denhardt's reagent, 2% sodium dodecyl sulphate (SDS) and 100 mg/ml sheared salmon sperm DNA for at least 2 h at 421C and hybridized overnight at 421C with a minimum of 10 6 c.p.m./ml of 32 P-labelled complementary DNA (cDNA) probes. The cDNA probes used in this analysis were a 500-bp human MUC4 and a 780-bp human GAPDH (Choudhury et al., 2000) . Membranes were washed twice with 3 Â standard saline citrate (SSC), 0.1% SDS for 15 min at 421C; and then 2-3 times with 0.1 Â SSC, 0.1% SDS for 15 min at 601C. Expression of the MUC4 and GAPDH mRNA was quantified by densitometry of autoradiograms using the ImageQuant software programme (Molecular Dynamics, Inc., Sunnyvale, CA, USA).
Immunoblot analysis and confocal fluorescence microscopy
The cells were lysed in ice-cold lysis buffer (50 mM Tris, 5 mM EDTA, 150 mM NaCl, 0.25% sodium deoxycholate; 1% NP40; pH 7.5) supplemented with protease inhibitor cocktail and kept at 41C for at least 30 min with intermittent vortexing. Cell lysates were processed further for protein extraction, estimation and resolution as described previously (Singh et al., 2004) . In brief, MUC4 protein was resolved on 2% SDSagarose gel under reducing conditions, while for phosphoglycerol kinase (PGK), SDS-polyacrylamide gel electrophoresis was performed on a 10.0% polyacrylamide gel under similar conditions. Resolved proteins were transferred to polyvinylpyrrolidone (PVDF) membranes and probed with antibodies specific for each of the target gene products. Signals were detected with the Enhanced Chemiluminescence kit. Confocal fluorescence microscopy to detect MUC4 expression was performed as previously described (Singh et al., 2004) .
siRNA-mediated inhibition of CFTR expression
An siRNA approach similar to that described by Elbashir et al. (2001) was used to confirm the inverse association between CFTR and MUC4 expression by silencing the CFTR gene expression in the CFPAC-PLJ-CFTR cell line. The coding sequence of CFTR was scanned to identify a genespecific 21-nucleotide sequence downstream of an AA sequence that possesses 63% GC content. A BLAST search confirmed that the selected sequence (corresponding to residues 78-98 downstream of ATG in GenBank accession number NM_000492.2) is not present in another transcript in GenBank database. The CFTR specific oligonucleotide 5 0 -GGAUACAGACAGCGCCUGGdTdT-3 0 and its corresponding oligonucleotide 5 0 -CCAGGCGCUGUCUGUAUC CdTdT-3 0 were synthesized and purified (Dharmacon Res., Lafayette, CO, USA). siRNA duplexes were formed by combining 30 ml of each 50 mM RNA oligonucleotide solution and 15 ml of 5 Â annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate) followed by heating for 1 min at 901C, then 1 h at 371C. At 24 h before transfection, the CFPAC-PLJ-CFTR cells were trypsinized and seeded in to six-well plates (5 Â 10 5 cells/well). The cells were transfected with siRNA duplexes using the TransIT-TKO Transfection reagent (Mirus Corp., Madison, WI, USA) in serum-containing and antibiotic-free media, as described by the manufacturer for adherent cell lines, and incubated for different time intervals. Cells were also transfected with the scrambled siRNAs to serve as treatment control. Total RNA was isolated from the transiently transfected cells and subjected to further analysis. Confocal immunofluorescence microscopy for MUC4 was also performed on coverslip grown CFTR siRNA-treated and -untreated cells.
RNA and protein turnover analysis For MUC4 mRNA and protein stability assays, 5 Â 10 5 cells were seeded in 10-cm Petri dishes and allowed to grow at 371C in 5% CO 2 , 95% air atmosphere. The medium was changed on alternate days until the cells reached 80-90% confluence. RNA and protein synthesis was inhibited by the addition of actinomycin D (8 mg/ml) and cycloheximide (10 mg/ml), respectively, and total RNA and protein were extracted at different time points (0-24 h). MUC4 mRNA and protein levels were evaluated by Northern and Western blot analyses as described above. Graphs were plotted as the percentage of starting mRNA and protein levels versus time after drug treatment. On the basis of plot extrapolation, the half-life is estimated to be at the point where 50% of the original level remains.
Transient transfection of cells and assay of transcriptional activity Promoter deletion mutants of MUC4 subcloned into the promoterless pGL3 basic vector (Promega) (Perrais et al., 2001) were utilised to analyse the promoter activity ( Figure 5 ). Transfections were performed using FuGene s reagent, according to the manufacturer's instructions. The cells were seeded at 1.0 Â 10 6 cells/well a day before the transfection. Total cell extracts were prepared after 48 h of incubation at 371C using 1 Â reagent lysis buffer (Promega). The results were corrected for transfection efficiency by co-transfecting 0.2 mg of pSVbGal vector (Promega). b-Galactosidase and luciferase activities were measured as previously described (Perrais et al., 2001) . Each plasmid was assayed in triplicate in at least three separate experiments.
Immunohistochemistry
Tissue sections (5 mm) cut from the paraffin blocks were stained with anti-MUC4 monoclonal antibody (8G7) for expression analysis by immunohistochemical (IHC) technique along with the appropriate control. The tissue sections (CF and normal) were processed for IHC analysis as described previously (Karan et al., 2003) .
Abbreviations CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MUC, mucin; PanIN, pancreatic intraepithelial neoplasm; PGK, phosphoglycerol kinase; siRNA, short interfering ribonucleic acid; SMC, sialo-mucin complex; UTR, untranslated region.
